BOTHELL, Wash., Jan. 23 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(OTC Bulletin Board: HXBM), a developer of bioactive peptides, today announced
its strategic milestones for 2006, which management recently presented to the
company's Board of Directors. The company believes that these milestones will
be an important step in transitioning the company from primarily a research
and development organization to a revenue generating commercial entity.
"With this announcement, we are outlining a comprehensive program to build
the company for the long-term, with a plan to increase revenues on the
consumer side of our business as well as prepare to take advantage of the
significant longer-term opportunity on the pharmaceutical side," said R.
Stephen Beatty, President and Chief Executive Officer of Helix BioMedix. "We
have the commitment of our Board as well as our scientific staff and look
forward to keeping our shareholders apprised of our progress throughout 2006."
Details of Helix BioMedix's 2006 milestones are as follows:
1. Launch five additional peptide-based products to market.
Helix BioMedix intends to work directly with cosmetic and consumer
product companies as well as with formulation or marketing entities to
sign licenses and supply agreements to introduce the company's
proprietary peptides in additional peptide-based products in the acne
and anti-aging markets.
2. Deliver two newly developed peptide-based ingredients to our marketing
and formulation partners.
Helix BioMedix will screen for new bioactive peptide ingredients that
have the potential to add value to our customers' product requirements.
After safety and formulation testing is completed, human panel testing
will be initiated.
3. Expand the use of our peptides into additional markets.
Helix BioMedix's research and development team intends to generate data
and market the company's existing peptides beyond the acne market,
targeting such markets as anti-aging, oral care and deodorant, among
others.
4. Invent additional peptides to expand and improve our future products.
Helix BioMedix plans to expand its product portfolio and technology
platform by filing patent applications on peptide classes for both
pharmaceutical and consumer product applications in 2006.
5. Advance preclinical testing of our "small molecule peptide" dermatology
application.
Helix BioMedix intends to perform toxicity and efficacy testing and
generate and publish data on its "small molecule peptide" at a wide
range of industry conferences throughout 2006. This particular peptide
is currently being targeted at dermatology applications.
"Peptides are playing a growing role in the search for new active
ingredients to bring added value and performance to skin care products," added
Mr. Beatty. "Our peptides have been proven to kill bacteria and fungi and to
stimulate aspects of healthy skin. The fact that they also consist of all
natural amino acids makes them even more appealing as a source of innovation
for the consumer products industry. Importantly, we have reduced the cost of
manufacturing, offering an attractive return on investment to these mass
market producers. While the consumer opportunity is exciting, we anticipate
that there is even more future potential for our peptides in the
pharmaceutical arena, where we are making strides in anti-infectives and wound
healing. With today's announcement of our strategic milestones, we believe we
have set the stage for a very exciting 2006."
About Helix BioMedix
Helix BioMedix, Inc. is an early-stage biopharmaceutical company that has
a portfolio of issued patents that covers six distinct classes of peptides,
including over 1 million unique peptide sequences. The company's mission is to
become the industry leader in developing and commercializing small proteins
known as bioactive peptides. The antimicrobial and wound healing properties of
these peptides qualify them for inclusion in a wide range of both
pharmaceutical and consumer products. The company is currently focused on the
development of selected peptides as topical anti-infectives and in wound
healing. Non-pharmaceutical applications being pursued by Helix BioMedix
include adjuvants for cosmetics/cosmeceuticals, personal care, plant health,
animal health and wide-spectrum biocides. More information about the company
and its proprietary peptides can be found on the company's website at
http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements which
are not historical facts) within the meaning of the Private Securities
Litigation Reform Act of 1995, including, without limitation, statements
regarding the company's 2006 strategic milestones and initiatives. These
forward-looking statements involve risks and uncertainties, including
activities, events or developments that the company expects, believes or
anticipates will or may occur in the future. A number of factors could cause
actual results to differ from those indicated in the forward-looking
statements, including the company's ability to successfully raise additional
capital, enter into revenue generating license agreements, continue its
research and development efforts, including pre-clinical and clinical studies,
and general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results or
developments may differ materially from those set forth in the forward-looking
statements. The company undertakes no obligation to publicly update or revise
forward-looking statements to reflect subsequent events or circumstances.
Contact:
Helix BioMedix, Inc.
David H. Kirske, 425-402-8400
dkirske@helixbiomedix.com
Investor Relations:
Cameron Associates
Alison Ziegler, 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com
CONTACT:
David H. Kirske of Helix BioMedix, Inc.,
+1-425-402-8400, dkirske@helixbiomedix.com; or Investor
Relations, Alison Ziegler of Cameron Associates for Helix
BioMedix, Inc., +1-212-554-5469, alison@cameronassoc.com
|
